Adenosine receptor ligands as potential therapeutics in asthma

Current Opinion in Investigational Drugs

Volumn 3, Issue 1, 2002, Pages 69-77

  Fozard, John R ^a   McCarthy, Clive ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

A1 receptor; A2A receptor; A2b receptor; A3 receptor; Adenosine; Asthma; Bronchoconstriction

Indexed keywords

2 [4 (2 CARBOXYETHYL)PHENETHYLAMINO]ADENOSINE 5' (N ETHYLCARBOXAMIDE); 3 ISOBUTYL 8 PYRROLIDINOXANTHINE; 4 [3 [6 AMINO 9 (5 ETHYLCARBAMOYL 3,4 DIHYDROXYTETRAHYDRO 2 FURYL) 9H PURIN 2 YL] 2 PROPYNYL]CYCLOHEXANECARBOXYLIC ACID METHYL ESTER; ADENOSINE A1 RECEPTOR; ADENOSINE A2 RECEPTOR ANTAGONIST; ADENOSINE A2A RECEPTOR; ADENOSINE A2A RECEPTOR AGONIST; ADENOSINE A2B RECEPTOR; ADENOSINE A2B RECEPTOR AGONIST; ADENOSINE A2B RECEPTOR ANTAGONIST; ADENOSINE A3 RECEPTOR; ADENOSINE A3 RECEPTOR ANTAGONIST; ADENOSINE RECEPTOR; ANTIASTHMATIC AGENT; ANTISENSE OLIGODEOXYNUCLEOTIDE; BUDESONIDE; EPI 2010; GLUCOCORTICOID; GW 328267; LIGAND; N (4 CYANOPHENYL) 2 [4 (2,3,6,7 TETRAHYDRO 2,6 DIOXO 1,3 DIPROPYL 1H PURIN 8 YL)PHENOXY]ACETAMIDE; REGADENOSON; THEOPHYLLINE; UNCLASSIFIED DRUG;

ASTHMA; BRONCHOSPASM; CARDIOVASCULAR DISEASE; CENTRAL NERVOUS SYSTEM DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; DRUG ACTIVATION; DRUG ACTIVITY; DRUG EFFECT; DRUG EFFICACY; DRUG INDUSTRY; DRUG INHIBITION; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DRUG TOLERABILITY; EVIDENCE BASED MEDICINE; GASTROINTESTINAL DISEASE; HUMAN; IN VITRO STUDY; IN VIVO STUDY; KIDNEY DYSFUNCTION; METABOLIC DISORDER; NONHUMAN; PATHOPHYSIOLOGY; RECEPTOR DOWN REGULATION; RECEPTOR OCCUPANCY; REVIEW; TISSUE DISTRIBUTION; ANIMAL; DRUG ANTAGONISM; DRUG POTENTIATION; METABOLISM; METHODOLOGY; PHARMACEUTICS; STATISTICS;

ANIMAL; ASTHMA; HUMAN; LIGANDS; RECEPTORS, PURINERGIC P1; TECHNOLOGY, PHARMACEUTICAL; ANIMALS; HUMANS;

EID: 0035985601     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (115)

1. Adenosine and the airways in asthma
2. The role of adenosine in asthma
3. Adenosine receptor ligands: Potential as therapeutic agents in asthma and COPD
4. Why do asthmatic subjects respond so strongly to inhaled adenosine?
5. Therapy of bronchial asthma with adenosine receptor agonists or antagonists
6. Receptors for purines and pyrimidines
7. Adenosine receptors
8. Structure and function of adenosine receptors and their genes
9. Adenosine receptor-mediated bronchoconstriction and bronchial hyperresponsiveness in allergic rabbit model
10. 1 receptor
11. Characterization of adenosine receptors involved in adenosine-induced bronchoconstriction in allergic rabbits
12. DNA antisense therapy for asthma in an animal model
13. Species differences in adenosine receptor-mediated bronchoconstrictor responses
14. 1 receptor mediated inhibition of surfactant secretion in rat Type II pneumocytes
15. 2 generation, respectively
16. 2 receptors
17. 1-adenosine receptor antagonists
18. Insight into adenosine receptor function using antisense and gene-knockout approaches
19. Respirable antisense oligonucleotides
20. Adenosine receptors, blood vessel and inflammation
21. 2A adenosine receptors in inflammation
22. Molecular approach to adenosine receptors: Receptor-mediated mechanisms of tissue protection
23. 2 receptors adenosine inhibits the upregulation of Mac-1 (CD11b/CD18) expression on fMLP stimulated neutrophils
24. Functional characterization of three adenosine receptor types
25. 2A receptors mediate the inhibitory effect of adenosine on formyl-Met-Leu-Phe-stimulated respiratory burst in neutrophil leucocytes
26. 3 receptors
27. Further pharmacological characterization of the adenosine receptor subtype mediating inhibition of oxidative burst in isolated human neutrophils
28. 2A subtype adenosine receptor in the anti-inflammatory interactions of CGS 21680, cyclopentyladenosine, and IBMECA with human neutrophils
29. Inhibitory effect of adenosine on degradulation of human cultured mast cell upon cross-linking of Fc epsilon RI
30. Differential regulatory effects of adenosine on cytokine release by activated human monocytes
31. T-cells in the lung
32. 2A extracellular adenosine receptor-mediated signaling in adenosine-mediated inhibition of T-cell activation and expansion
33. 2A purinergic receptor-mediated signaling in murine T cells
34. 2A receptor monoclonal antibodies
35. 2A receptor agonist, on airways inflammation induced by allergen in actively sensitised Brown Norway rats
36. Product development pipeline February 2001
37. 2A adenosine receptor agonists
38. 2A receptor agonists
39. 2A receptors
40. 2a receptor
41. 2B receptor activation selectively stimulates cAMP formation and inhibition of TNFα release in THP-1 cells
42. Adenosine inhibits marcophage colony-stimulating factor-dependent proliferation of macrophages throught the induction of p27kip-1 expression
43. 2B adenosine receptor expression in macrophages: A mechanism of macrophage deactivation
44. 2B adenosine receptors in human lymphocytes: Their role in T cell activation
45. 2B receptors in the guinea pig aorta
46. 5′-N-substituted carboxamidoadenosines as agonists for adenosine receptors
47. 2B receptors
48. 2B receptors: A novel therapeutic target in asthma?
49. 3 adenosine receptor is the unique adenosine receptor which facilitates release of allergic mediators in mast cells
50. 3 adenosine receptor gene in mice and its effect on stimulated inflammatory cells
51. Adenosine
52. 2-purinoceptor mediated mechanism
53. Regulation of human basophil and lung mast cell function by adenosine
54. 2b receptors evoke interleukin-8 secretion in human mast cells: An enprophylline-sensitive mechanism with implications for asthma
55. 2B adenosine receptor subtypes
56. Recent advances in our understanding of the use of theophylline in the treatment of asthma
57. Theophylline for the treatment of bronchial asthma: Present status
58. Theophylline
59. 2B receptor. Derivatives of the triazolotriazine adenosine receptor antagonist ZM241385 with high affinity
60. 2B adenosine receptor antagonists
61. 2B adenosine receptors
62. 3 receptor subtypes
63. 2B receptor
64. 2B adenosine receptor
65. MRS 1754, a selective A2b adenosine receptor antagonist, inhibits degranulation of cultured human but not murine mast cells
66. 2B receptor antagonist 3-isobutyl-8-pyrrolidinoxanthine (IPDX)
67. 3 receptors: Pharmacological properties, species differences and receptor functions
68. 3 adenosine receptors
69. 3 adenosine receptor ligands: History and perspectives
70. 3 adenosine receptors on human eosinophils elevates intracellular calcium
71. 3 receptor stimulation on human eosinophils isolated from non-asthmatic or asthmatic donors
72. Pathophysiology of the inflammatory response
73. The epidemic of allergy and asthma
74. 3 receptors on human eosinophils mediate inhibition of degranulation and superoxide anion release
75. 3 receptor stimulation inhibits migration of human eosinophils
76. 3 adenosine receptor activation triggers phosphorylation of protein kinase B and protects rat basophilic leukemia 2H3 mast cells from apoptosis
77. Release of adenosine from human sensitized lung fragments and its effect on antigen-induced mediator release
78. Mechanism of airway hyperresponsiveness to adenosine induced by allergen challenge in actively sensitised Brown Norway rats
79. Evidence for an atypical receptor mediating the augmented response to adenosine induced by allergen challenge in actively sensitised Brown Norway rats
80. Preparation of 2-(purin-9-yl)-tetrahydrofuran-3,4-diol nucleosides as antiinflammatory agents and agonists adenosine receptors
81. Preparation of adenosine derivatives as antiinflammatory agents
82. Preparation of 2-(purin-9-yl)-tetrahydrofuran-3,4-diol nucleosides as antiinflammatory agents
83. Preparation of 2-(purin-9-yl)-tetrahydrofuran-3,4-diol nucleosides as antiinflammatory agents
84. Preparation of 2-(purin-9-yl)-tetrahydrofuran-3,4-diol nucleosides as antiinflammatory agents
85. Preparation of 2-(purin-9-yl)-tetrahydrofuran-3,4-diol nucleosides as antiinflammatory agents
86. Preparation and anti-inflammatory activity of 2-(purin-9-yl)-tetrahydrofuran-3,4-derivatives
87. Preparation of 2-(purin-9-yl)-tetrahydrofuran-3,4-diol nucleosides as antiinflammatory agents
88. 2a receptor agonists
89. 2a receptor agonists
90. Preparation of purine nucleosides as antiinflammatory agents
91. 2 receptor
92. 2a receptor agonists
93. 2a receptor agonists
94. 2a receptor agonists for purposes of imaging the heart
95. 2a receptor agonists for purposes of imaging the heart
96. 2a receptor agonists for purposes of imaging the heart
97. 2a receptor agonists for purposes of imaging the heart
98. Compositions for treating inflammatory response
99. Substituted 2-thio-3,5-dicyano-4-aryl-6-aminopyridines and the use thereof as adenosine receptor ligands
100. 2B adenosine receptors
101. 2B adenosine receptors
102. 2 receptor antagonists for the treatment of diabetes
103. Preparation of fused imidazole compounds and remedies for diabetes mellitus
104. Medicinal compositions promoting bowel movement
105. Method for improving insulin sensitivity using an adenosine receptor antagonist
106. 3 receptor antagonists
107. 3 adenosine receptor subtype-specific antagonists for alteration of eosinophil cytokine-induced hypersensitivity
108. Human adenosine receptor antagonists
109. 3 receptor, process for the preparation of the same and uses thereof
110. 3 antagonists
111. 3 receptor antagonists
112. 3 adenosine receptor antagonists
113. Preparation of dihydropyridines, pyridines, benzopyranones, and triazoloquinazolines for use as adenosine receptor antagonists
114. 3 receptor antagonists
115. 3 receptor antagonists